(3.239.33.139) 您好!臺灣時間:2021/03/08 17:33
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:林長慶
研究生(外文):LIN, CHANG-CHING
論文名稱:Src蛋白抑制劑:AC93253衍生物活性評估及吲哚衍生物合成
論文名稱(外文):Src Protein Inhibitors:Biological Evaluation of AC93253 Derivatives and the Synthesis of Indole Analogs
指導教授:吳雨珊吳雨珊引用關係
指導教授(外文):WU, YU-SHAN
口試委員:陳健尉楊定亞
口試委員(外文):Jeremy J. W. ChenYANG, DING-YAH
口試日期:2017-10-27
學位類別:碩士
校院名稱:東海大學
系所名稱:化學系
學門:自然科學學門
學類:化學學類
論文種類:學術論文
論文出版年:2017
畢業學年度:106
語文別:中文
論文頁數:158
中文關鍵詞:Src蛋白抑制劑
外文關鍵詞:Src Protein Inhibitors
相關次數:
  • 被引用被引用:0
  • 點閱點閱:65
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
肺癌是所有癌症中死亡率最高的。Src蛋白是一個酪胺酸激酶,在肺癌細胞中Src蛋白較一般細胞活躍,會導致癌細胞的增生、移動和血管新生,因此Src可以作為肺癌治療的標靶。先前研究中利用電腦模擬輔助藥物設計程式(CADD)和生物活性實驗的方式,得到對Src蛋白具有抑制性的兩種化合物AC93253及WY1339。
本研究首先利用西方墨點法和細胞存活分析來探討一系列AC93253衍生物,其中衍生物A10有最佳的Src抑制能力和肺癌細胞毒殺效果。另外在低濃度下,A10對肺癌細胞的細胞功能皆有顯著的抑制能力,包括癌細胞的增生、移動、轉移、及細胞群落形成的能力。
本研究也以WY1339為先導化合物,設計合成出一系列以吲哚為主體,不同長度、不同取代基的衍生物。根據生物活性的結果,WY1339結構中吲哚6號位置的取代基消失會降低抑制肺癌細胞的效果。將吲哚上6號位置的苯環取代基更改為苄基時會降低對肺癌細胞株A549的抑制能力。而所有衍生物中,L43對A549具有較佳的毒殺效果(IC50為39.91 μM)。

Lung cancer is the leading cause of cancer death. In lung cancer cells, Src protein is more active than in normal cells as it induces cell proliferation, migration and angiogenesis. It is thus a good target for the development of lung cancer treatment. In previous research, we have identified two compounds, AC93253 and WY1339 by CADD as Src inhibitors and their inhibitory activities were verified by in vitro studies.

In this study, western blot and cell survival analysis were performed to a series of AC93253 derivatives. Derivative A10 was found to exhibit most Src inhibitory activity and cytotoxicity against lung cancer cells. At low concentrations, A10 significantly inhibited lung cancer cell functions such as proliferation, migration, invasion, and colony formation.

We have taken WY1339 as lead compound and further designed a series of substituted indole derivative. MTT assay revealed that when there was no substituents or replacement of phenyl by benzyl group at 6th position of indole, the cytotoxicity against lung cancer cells decreased drastically. Within all the derivative synthesized, L43 exhibited better activity against A549 lung cancer cell line with IC50 of 39.91 μM.

第一章 、緒論...................................1
第一節 、肺癌.................................1
第二節 、Src蛋白..............................3
第三節 、Src蛋白與肺癌.........................7
第四節 、Src蛋白的結構........................10
第五節 、先導化合物的發現......................12
第二章 、篩選並評估AC93253衍生物對肺癌抑制能力.....15
第一節 、實驗目的和實驗架構.....................17
第二節 、實驗材料與方法.........................19
第三節 、實驗結果..............................30
第四節 、討論..................................30
第三章 、吲哚衍生物合成與構效關係..................47
第一節 、實驗材料與方法.........................49
第二節 、結果與討論.............................71
第一項 、有機合成.............................71
第二項 、生物活性與構效關係探討................83
第四章 、結論....................................96
第五章 、未來展望.................................98
第六章 、文獻資料.................................99




1.世界衛生組織 [http://www.who.int/mediacentre/factsheets/fs297/en/]
2.Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J
Clin 2015, 65(1):5-29.
3.Collins LG, Haines C, Perkel R, Enck RE: Lung cancer: diagnosis and
management. Am Fam Physician 2007, 75(1):56-63.
4.Stinchcombe TE: Novel agents in development for advanced non-small
cell lung cancer. Ther Adv Med Oncol 2014, 6(5):240-253.
5.Cancer Genome Atlas Research N: Comprehensive molecular profiling of
lung adenocarcinoma. Nature 2014, 511(7511):543-550.
6.Rubin H: Quantitative relations between causative virus and cell in
the Rous no. 1 chicken sarcoma. Virology 1955, 1(5):445-473.
7.Czernilofsky AP, Levinson AD, Varmus HE, Bishop JM, Tischer E, Goodman
HM: Nucleotide sequence of an avian sarcoma virus oncogene (src) and
proposed amino acid sequence for gene product. Nature
1980,287(5779):198-203.
8.Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470-480.
9.Martin GS: The hunting of the Src. Nat Rev Mol Cell Biol 2001,
2(6):467-475.
10.Bishop JM: Cellular oncogenes and retroviruses. Annu Rev Biochem 1983,
52:301-354.
11.Sen B, Johnson FM: Regulation of SRC family kinases in human cancers.
J Signal Transduct 2011, 2011:865819.
12.Roskoski R, Jr.: Src protein-tyrosine kinase structure and regulation.
Biochem Biophys Res Commun 2004, 324(4):1155-1164.
13.Garrett RH, Grisham CM: Biochemistry 6Ed; 2006.
14.Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Jr., Gallick
GE: Decreased Src tyrosine kinase activity inhibits malignant human
ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res
1999, 5(8):2164-2170.
15.Vidal M, Warner S, Read R, Cagan RL: Differing src signaling levels
have distinct outcomes in drosophila. Cancer Res 2007, 67(21):10278-
10285.
16.Summy JM, Gallick GE: Treatment for advanced tumors: Src reclaims
center stage. Clinical Cancer Research 2006, 12(5):1398-1401.
17.Lu Y, Wang H, Mills GB: Targeting PI3K-AKT pathway for cancer therapy.
Rev Clin Exp Hematol 2003, 7(2):205-228.
18.Cao X, Tay A, Guy GR, Tan YH: Activation and association of Stat3 with
Src in v-Src-transformed cell lines. Mol Cell Biol 1996, 16(4):1595-
1603.
19.Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB: Dasatinib (BMS-
354825) selectively induces apoptosis in lung cancer cells dependent
on epidermal growth factor receptor signaling for survival. Cancer Res
2006, 66(11):5542-5548.
20.Mazurenko NN, Kogan YA, Zborovskaya IB, Sukhova NM, Kiselev FL:
Identification of C-Src Gene-Encoded Protein in Human Lung-Tumors. Vop
Onkol+ 1991, 37(6):683-&.
21.Frame MC: Src in cancer: deregulation and consequences for cell
behaviour. Bba-Rev Cancer 2002, 1602(2):114-130.
22.Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W,
Ma L, Wistuba, II, Johnson FM, Kurie JM: SRC-family kinases are
activated in non-small cell lung cancer and promote the survival of
epidermal growth factor receptor-dependent cell lines. Am J Pathol
2007, 170(1):366-376.
23.Mendelsohn J, Baselga J: Status of epidermal growth factor receptor
antagonists in the biology and treatment of cancer. J Clin Oncol 2003,
21(14):2787-2799.
24.Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA,
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to gefitinib.
New Engl J Med 2004, 350(21):2129-2139.
25.Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL: Expression of
Pp60c-Src in Human Small-Cell and Non-Small-Cell Lung Carcinomas. Eur
J Cancer 1992, 28a(2-3):372-377.
26.JAK-STAT Signaling Pathway [https://www.tocris.com/pathways/jak-stat-
signaling-pathway]
27.Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ,
Yoneyama H, Uchida N, Fujita J et al: pp60(c-src) activation in lung
adenocarcinoma. Eur J Cancer 2003, 39(10):1447-1455.
28.Visser CJT, Rijksen G, Woutersen RA, DeWeger RA: Increased
immunoreactivity and protein tyrosine kinase activity of the
protooncogene pp60(c-src) in preneoplastic lesions in rat pancreas.
Lab Invest 1996, 74(1):2-11.
29.Yu HT, Rosen MK, Shin TB, Seideldugan C, Brugge JS, Schreiber SL:
Solution Structure of the Sh3 Domain of Src and Identification of Its
Ligand-Binding Site. Science 1992, 258(5088):1665-1668.
30.Xu WQ, Harrison SC, Eck MJ: Three-dimensional structure of the
tyrosine kinase c-Src. Nature 1997, 385(6617):595-602.
31.郭昕銓: 設計並合成吲哚及吲哚啉衍生物作為具抗癌潛力藥物之新型Src蛋白抑制劑.
tunghai university; 2015.
32.謝昀臻: 設計合成萘與苯並噻唑衍生物作為非小細胞肺癌治療之Src蛋白抑制劑.
tunghai university; 2015.
33.Lin SY, Chang HH, Lai YH, Lin CH, Chen MH, Chang GC, Tsai MF, Chen
JJW: Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple
Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. Plos One
2015, 10(5).
34.Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang DX, Jing T, Yu DH:
ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src
activation that confer breast cancer metastasis. Cancer Res 2005,
65(5):1858-1867.
35.Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C,
Castaneda S, Inigo I, Kan D et al: Dasatinib (BMS-354825)
pharmacokinetics and pharmacodynamic biomarkers in animal models
predict optimal clinical exposure. Clin Cancer Res 2006, 12(23):7180-
7186.
36.Johnson FM, Saigal B, Talpaz M, Donato NJ: Dasatinib (BMS-354825)
tyrosine kinase inhibitor suppresses invasion and induces cell cycle
arrest and apoptosis of head and neck squamous cell carcinoma and non-
small cell lung cancer cells. Clin Cancer Res 2005, 11(19 Pt 1):6924-
6932.
37.Summy JM, Gallick GE: Treatment for advanced tumors: SRC reclaims
center stage. Clin Cancer Res 2006, 12(5):1398-1401.
38.Botta G, De Santis LP, Saladino R: Current advances in the synthesis
and antitumoral activity of SIRT1-2 inhibitors by modulation of p53
and pro-apoptotic proteins. Curr Med Chem 2012, 19(34):5871-5884.
39.Choi YH, Kim H, Lee SH, Jin YH, Lee KY: Src regulates the activity of
SIRT2. Biochem Biophys Res Commun 2014, 450(2):1120-1125.
40.Fatima A, Abdul ABH, Abdullah R, Karjiban RA, Lee VS: Binding Mode
Analysis of Zerumbone to Key Signal Proteins in the Tumor Necrosis
Factor Pathway. Int J Mol Sci 2015, 16(2):2747-2766.
41.Pardo C, Pirat C, Elguero J: The synthesis of a linear Troger's Base
derived from naphthalene: 7H-15H-6,14-methanodinaphtho[2,3-b : 2 ',3
'-f][1,5]diazocine. J Heterocyclic Chem 2007, 44(6):1303-1307.
42.Bergman J, Desarbre E, Koch E: Synthesis of indolo[3,2-a]pyrrolo[3,4-
c]carbazole in one step from indole and maleimide. Tetrahedron 1999,
55(8):2363-2370.
43.Matos K, Soderquist JA: Alkylboranes in the Suzuki-Miyaura coupling:
Stereochemical and mechanistic studies. J Org Chem 1998, 63(3):461-
470.
44.Miyaura N, Suzuki A: Palladium-Catalyzed Cross-Coupling Reactions of
Organoboron Compounds. Chem Rev 1995, 95(7):2457-2483.
45.Molander GA, Elia MD: Suzuki-Miyaura cross-coupling reactions of
benzyl halides with potassium aryltrifluoroborates. J Org Chem 2006,
71(24):9198-9202.
46.Negishi E: Handbook of Organopalladium Chemistry for Organic
Synthesis; 2002.
47.Casado AL, Espinet P: On the configuration resulting from oxidative
addition of RX to Pd(PPh3)(4) and the mechanism of the cis-to-trans
isomerization of [PdRX(PPh3)(2)] complexes (R equals aryl, X equals
halide). Organometallics 1998, 17(5):954-959.
48.Ridgway BH, Woerpel KA: Transmetalation of alkylboranes to palladium
in the Suzuki coupling reaction proceeds with retention of
stereochemistry. J Org Chem 1998, 63(3):458-460.
49.Stille JK, Lau KSY: Mechanisms of Oxidative Addition of Organic
Halides to Group-8 Transition-Metal Complexes. Accounts Chem Res 1977,
10(12):434-442.
50.Hayashi T, Konishi M, Kobori Y, Kumada M, Higuchi T, Hirotsu K:
Dichloro[1,1'-Bis(Diphenylphosphino)Ferrocene]Palladium-(Ii) - an
Effective Catalyst for Cross-Coupling of Secondary and Primary Alkyl
Grignard and Alkylzinc Reagents with Organic Halides. J Am Chem Soc
1984, 106(1):158-163.
51.An YL, Shao ZY, Cheng J, Zhao SY: Highly Efficient Aluminum
Trichloride Catalyzed Michael Addition of Indoles and Pyrroles to
Maleimides. Synthesis-Stuttgart 2013, 45(19):2719-2726.
52.Schindler CS, Diethelm S, Carreira EM: Nucleophilic Opening of
Oxabicyclic Ring Systems. Angew Chem Int Edit 2009, 48(34):6296-6299.

電子全文 電子全文(網際網路公開日期:20221231)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
無相關期刊
 
無相關點閱論文
 
系統版面圖檔 系統版面圖檔